Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

News provided by

Feb 23, 2015, 04:05 ET

DUBLIN, Feb. 23, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.

Cowen and Company 35^th Annual Healthcare Conference in Boston, MA on Monday, March 2, 2015 at 1:30 p.m. EST / 6:30 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2015 at 2:05 p.m. EDT / 6:05 p.m. GMT. Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update.

A live audio webcast of each presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors & Media section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals plc